Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study

Area of Science:

• Neuro-oncology
• Immunology
• Hematology

Background:

• Immunodeficiency-associated primary CNS lymphoma (ID-PCNSL) is a distinct subtype lacking extensive research and prognostic models.
• Existing models for immunocompetent PCNSL may not accurately stratify ID-PCNSL patients.

Purpose of the Study:

• To characterize the clinicopathologic features of ID-PCNSL.
• To identify prognostic factors and develop a predictive model for ID-PCNSL.
• To evaluate treatment outcomes, particularly with immune reconstitution and chemotherapy.

Main Methods:

• International retrospective multi-center study of 308 ID-PCNSL cases.
• Integration of clinical, radiological, and pathological data.
• Multivariable Cox regression and development of a prognostic score based on age, Karnofsky Performance Status (KPS), and Epstein-Barr virus (EBV) status.

Main Results:

• All tumors were diffuse large B-cell lymphomas, with 79.2% EBV positivity.
• Rituximab-methotrexate (RM)-based chemotherapy with immune reconstitution showed high response rates and prolonged progression-free survival.
• A novel prognostic score (age, KPS < 70, EBV positivity) significantly stratified overall survival (median 135, 29, and 3 months).

Conclusions:

• ID-PCNSL is characterized by diffuse large B-cell lymphoma, often EBV-positive.
• Immune reconstitution combined with RM chemotherapy is associated with improved outcomes in ID-PCNSL.
• The developed prognostic score offers improved risk stratification for ID-PCNSL compared to existing models.